HK1109059A1 - Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof - Google Patents

Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof

Info

Publication number
HK1109059A1
HK1109059A1 HK07114046.8A HK07114046A HK1109059A1 HK 1109059 A1 HK1109059 A1 HK 1109059A1 HK 07114046 A HK07114046 A HK 07114046A HK 1109059 A1 HK1109059 A1 HK 1109059A1
Authority
HK
Hong Kong
Prior art keywords
tyrosine kinase
protein tyrosine
epothilones
combinations
kinase inhibitors
Prior art date
Application number
HK07114046.8A
Other languages
English (en)
Inventor
Jerry Min-Jian Huang
Anandhi Ranganathan Johri
Ronald Richard Linnartz
Paul M J Mcsheehy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118322&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1109059(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1109059A1 publication Critical patent/HK1109059A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK07114046.8A 2004-11-30 2007-12-21 Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof HK1109059A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63183704P 2004-11-30 2004-11-30
PCT/US2005/042975 WO2006060331A1 (en) 2004-11-30 2005-11-28 Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
HK1109059A1 true HK1109059A1 (en) 2008-05-30

Family

ID=36118322

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07114046.8A HK1109059A1 (en) 2004-11-30 2007-12-21 Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof

Country Status (29)

Country Link
US (2) US20080139587A1 (xx)
EP (1) EP1819331B1 (xx)
JP (1) JP2008521826A (xx)
KR (1) KR20070088653A (xx)
CN (1) CN101065127A (xx)
AT (1) ATE445398T1 (xx)
AU (1) AU2005312061B2 (xx)
BR (1) BRPI0518733A2 (xx)
CA (1) CA2584163A1 (xx)
CY (1) CY1110559T1 (xx)
DE (1) DE602005017181D1 (xx)
DK (1) DK1819331T3 (xx)
ES (1) ES2333348T3 (xx)
HK (1) HK1109059A1 (xx)
HR (1) HRP20100012T1 (xx)
IL (1) IL183138A (xx)
JO (1) JO2596B1 (xx)
MA (1) MA29032B1 (xx)
MX (1) MX2007006371A (xx)
NO (1) NO20073370L (xx)
NZ (1) NZ554552A (xx)
PL (1) PL1819331T3 (xx)
PT (1) PT1819331E (xx)
RU (1) RU2423980C2 (xx)
SI (1) SI1819331T1 (xx)
TN (1) TNSN07212A1 (xx)
TW (1) TW200630091A (xx)
WO (1) WO2006060331A1 (xx)
ZA (1) ZA200703196B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781237A (zh) 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
CN102134246A (zh) * 2011-01-06 2011-07-27 王文怡 一种埃博霉素衍生物及其制备和药物应用
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EP2879675B1 (en) 2012-08-06 2019-11-13 Duke University Compounds and methods for targeting hsp90
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
EP3826988A4 (en) 2018-07-24 2023-03-22 Hygia Pharmaceuticals, LLC COMPOUNDS, DERIVATIVES AND ANALOGS AGAINST CANCER
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022047259A1 (en) 2020-08-28 2022-03-03 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
GB2617409B (en) 2022-04-27 2024-06-26 Cancertain Ltd Method for predicting responsiveness to therapy
WO2024030441A1 (en) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE60130017T2 (de) * 2000-11-22 2008-05-15 Novartis Ag Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
CN1511036B (zh) * 2001-02-27 2010-05-05 诺瓦提斯公司 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
IL161462A0 (en) * 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
WO2003103712A1 (en) * 2002-06-01 2003-12-18 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
JO2596B1 (en) 2011-02-27
WO2006060331A1 (en) 2006-06-08
CA2584163A1 (en) 2006-06-08
EP1819331A1 (en) 2007-08-22
TW200630091A (en) 2006-09-01
ZA200703196B (en) 2009-08-26
DE602005017181D1 (de) 2009-11-26
IL183138A0 (en) 2008-04-13
AU2005312061B2 (en) 2009-09-03
AU2005312061A1 (en) 2006-06-08
ES2333348T3 (es) 2010-02-19
EP1819331B1 (en) 2009-10-14
PT1819331E (pt) 2009-11-30
SI1819331T1 (sl) 2010-02-26
MA29032B1 (fr) 2007-11-01
JP2008521826A (ja) 2008-06-26
NZ554552A (en) 2011-05-27
KR20070088653A (ko) 2007-08-29
RU2423980C2 (ru) 2011-07-20
MX2007006371A (es) 2007-06-20
TNSN07212A1 (en) 2008-11-21
PL1819331T3 (pl) 2010-03-31
BRPI0518733A2 (pt) 2008-12-02
ATE445398T1 (de) 2009-10-15
HRP20100012T1 (hr) 2010-02-28
IL183138A (en) 2011-03-31
US20110190312A1 (en) 2011-08-04
US20080139587A1 (en) 2008-06-12
RU2007124492A (ru) 2009-04-10
NO20073370L (no) 2007-06-29
CN101065127A (zh) 2007-10-31
CY1110559T1 (el) 2015-04-29
DK1819331T3 (da) 2010-01-04

Similar Documents

Publication Publication Date Title
ZA200703196B (en) Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
WO2011046964A3 (en) Inhibitors of bruton's tyrosine kinase
WO2008121742A3 (en) Inhibitors of bruton's tyrosine kinase
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
AP2332A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors.
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
HK1139036A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
TW200801008A (en) Protein kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
GB0421525D0 (en) Inhibitors of protein kineses
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
WO2006052810A3 (en) Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EP1922086A4 (en) TARGETED PROTEIN KINASE C HEMMER AND ITS USES
WO2007086943A3 (en) Wortmannin conjugates and uses thereof
WO2007050673A3 (en) Cyclin dependent kinase inhibitors
ZA200704971B (en) Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
TNSN07025A1 (en) Epothilone combinations
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
AU2005907140A0 (en) Use of Naltrexone for Treating Alzheimers Disease
AU2005907190A0 (en) Use of Naltrexone for Treating Alzheimers Disease

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131128